Skip to content
    Nextech logo

    Nextech

    Zurich, SwitzerlandFounded 1998
    www.nextechinvest.comLinkedIn
    Biotech & Life SciencesHealthcare

    Nextech Invest is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. Founded in 1998, it invests almost exclusively in oncology and oncology-adjacent therapeutics, diagnostics, and medical devices, from company inception through crossover rounds across the US and Europe.

    58% of their portfolio is in Biotech & Life Sciences. Deal activity increased 300% year-over-year (8 deals in the last 12 months). Their most common stage is series-b (42% of deals). Average disclosed round size is $85.5M (across 82 rounds with reported amounts).

    Find people at Nextech on Goldilocks AI

    Portfolio

    61

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    8

    Team

    KP

    Kanishka Pothula

    Managing Partner

    RS

    Rocco Sgobbo

    Managing Partner, COO

    NB

    Niresh Berinpanathan

    Principal

    SS

    Sarah Soo-Hoo, MD

    Principal

    JK

    Jules Ketterlin

    Associate, Portfolio Management

    AJ

    Alessia Jaeggli

    Executive Assistant

    AN

    Amy Nelson

    Executive Assistant

    BC

    Brian Chen

    Finance & Operations Manager

    KK

    Kelsey Kalish

    Executive Assistant

    MW

    Marco Weibel

    Chief Financial Officer

    MP

    Meriel Peccolo

    Controller

    NL

    Nazira Landolt-Askarova

    Finance & Accounting Specialist

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    93 investments
    CompanyRoundAmountDate
    Khartis Therapeutics logoKhartis TherapeuticsSeries B$50MAug 2026
    Flare Therapeutics logoFlare TherapeuticsSeries C—Jun 2026
    Stipple Bio logoStipple BioSeries A$100MApr 2026
    SStippleSeries A$100MApr 2026
    AAtavistikSeries B—Mar 2026
    Atavistik Bio logoAtavistik BioSeries B$120MDec 2025
    Tubulis logoTubulisSeries C—Oct 2025
    TTubulis GmbHSeries C—Oct 2025
    AAlpha-9 Oncology, Inc.Series C$175MOct 2024
    AAlpha-9Series C$175MOct 2024
    Alterome Therapeutics logoAlterome TherapeuticsSeries B$35MApr 2024
    AAlteromeSeries B$132MApr 2024
    Latigo Biotherapeutics logoLatigo BiotherapeuticsSeries A$135MFeb 2024
    ProfoundBio logoProfoundBioSeries B$112MFeb 2024
    Alterome Therapeutics logoAlterome TherapeuticsSeries B$132MJan 2024
    AAlpha-9 Oncology, Inc.Series C$175MJan 2024
    Mariana Oncology logoMariana OncologySeries B$175MSep 2023
    K36 Therapeutics logoK36 TherapeuticsSeries B$70MJun 2023
    KK36Series B$70MJun 2023
    Flare Therapeutics logoFlare TherapeuticsSeries B$123MMar 2023
    AAlpha-9 TheranosticsSeries B$75MDec 2022
    AAlpha-9Series B$75MDec 2022
    IDRx logoIDRxSeries A—Aug 2022
    MOMA Therapeutics logoMOMA TherapeuticsSeries B$150MMay 2022
    Tubulis logoTubulisSeries B—May 2022
    Page 1 of 4

    Top Co-Investors

    RA Capital Management28 shared
    Casdin Capital27 shared
    OrbiMed19 shared
    The Column Group15 shared
    Wellington Management15 shared
    Samsara BioCapital14 shared
    The Invus Group, LLC13 shared
    Alexandria Venture Investments12 shared
    Logos Capital11 shared
    Canaan Partners11 shared
    Foresite Capital11 shared
    Cormorant Asset Management10 shared
    Boxer Capital10 shared
    Euclidean Capital8 shared
    Third Rock Ventures8 shared
    BVF Partners L.P.8 shared
    Perceptive Advisors8 shared
    Surveyor Capital8 shared
    Frazier Life Sciences7 shared
    Versant Ventures7 shared

    Last updated: 20 October 2026